Sensei Biotherapeutics Reports Full Year 2024 Financial Results and Update on Clinical Progress
Clinical Trial Progress: Sensei Biotherapeutics reported promising preliminary efficacy data for solnerstotug in a Phase 1/2 trial, showing durable responses and tumor shrinkage in patients resistant to PD-(L)1 therapy, with a target enrollment achieved and full data expected by the end of 2025.
Financial Overview: The company maintains a strong cash position, expecting to fund operations into the second quarter of 2026, while reporting a net loss of $30.2 million for 2024, a decrease from the previous year's loss.
Trade with 70% Backtested Accuracy
Analyst Views on SNSE
About SNSE
About the author
Biotech Stocks Surge: Coherus Up 9.09% in After-Hours Trading
- Coherus Performance: Coherus Oncology, Inc. (CHRS) rose 9.09% in after-hours trading, closing at $1.73 with a $0.14 gain, indicating strong investor confidence in its future prospects.
- Sensei Biotech Surge: Sensei Biotherapeutics, Inc. (SNSE) surged 10.06% after hours, finishing at $12.47 with a $1.14 increase, reflecting positive market expectations for its products.
- uniQure Significant Jump: uniQure N.V. (QURE) posted a 9.96% rise in after-hours trading, closing at $24.95 with a $2.26 gain, suggesting investor optimism regarding its R&D progress.
- IO Biotech Strategic Exploration: Although IO Biotech, Inc. (IOBT) had no fresh news on Thursday, its stock still gained 4.19%, closing at $0.50, indicating market interest in its exploration of strategic alternatives, including potential mergers or asset sales.
What Caused Sensei Biotherapeutics (SNSE) Stock to Surge Nearly 63% in After-Hours Trading?
Sensei Biotherapeutics Stock Surge: Sensei Biotherapeutics Inc. (SNSE) saw a significant increase of 62.88% in after-hours trading, reaching $17.20, following a closing price of $10.56, which was up 21.38% for the day.
Cambrian BioPharma Share Sales: Cambrian BioPharma Inc., a 10% shareholder, filed two Form 144 documents indicating plans to sell 27,066 common shares valued at $235,744, with transactions to be executed through Fidelity Brokerage Services LLC.
Stock Performance Overview: The stock of Sensei Biotherapeutics has increased by 2.52% year-to-date and 46.26% over the past six months, with a market capitalization of $13.32 million and trading between $5 and $18.35 over the last year.
BBAI Stock Momentum: BigBear.ai (BBAI) is trending with a momentum ranking in the 48th percentile, indicating strong long-term gains and stable performance in both short and medium terms.
Healthcare and Biotech Stocks Surge in After-Hours Trading: Sensei, Praxis, Cooper, Vanda, Cue, ResMed
Sensei Biotherapeutics Surge: Sensei Biotherapeutics Inc. saw a significant after-hours increase of 62.9% to $17.20, following a previous rise and a report of a narrower third-quarter net loss compared to the previous year.
Praxis Precision Medicines Progress: Praxis Precision Medicines, Inc. rose 24.8% to $237.10 after positive EMBOLD study results led to an early recommendation for stopping the study, with plans for an NDA filing in early 2026.
CooperCompanies Financial Update: The CooperCompanies, Inc. climbed 13.0% to $87.01 after reporting a fourth-quarter net income decline but positive revenue growth, alongside a strategic review to enhance shareholder value.
Vanda Pharmaceuticals FDA Approval: Vanda Pharmaceuticals Inc. gained 7.5% to $5.59 after the FDA lifted a partial clinical hold on a protocol, allowing for expanded dosing of tradipitant following a successful dispute resolution request.
Sensei Biotherapeutics Launches Strategic Review Aimed at Enhancing Shareholder Value
Company Decision: Sensei Biotherapeutics has decided to discontinue the development of solnerstotug and is conducting a strategic review to explore alternatives for maximizing shareholder value, which may include asset sales or mergers.
Workforce Reduction: The company plans to implement a workforce reduction to conserve cash while retaining a small team to manage compliance and the orderly cessation of ongoing clinical trials.
CEO Statement: CEO John Celebi acknowledged the clinical potential of solnerstotug but emphasized the need to prioritize funding and shareholder value in light of current market conditions.
Forward-Looking Statements: The company has issued caution regarding forward-looking statements, highlighting the uncertainties involved in the strategic review process and the potential risks associated with workforce reductions and operational wind-downs.
Post-Market Jump: Turn Therapeutics Soars 134% Following Nasdaq Debut; Biotech Stocks Rise
Surge in Biotech Stocks: U.S.-listed biotech and healthcare stocks experienced significant after-hours gains, with Turn Therapeutics Inc. leading the way, surging 134.29% after its Nasdaq debut.
Momentum and Anticipation: Other companies like Talphera Inc. and Ionis Pharmaceuticals Inc. also saw notable increases, driven by momentum and upcoming presentations, indicating a strong interest in the biotech sector.
HC Wainwright & Co. Maintains Buy on Sensei Biotherapeutics, Raises Price Target to $30
Fastest News Alerts: Benzinga Pro offers real-time intelligence and news alerts to help traders stay informed and make winning trades in the stock market.
Exclusive Community Access: Joining Benzinga Pro connects users with over 10,000 serious traders and provides access to exclusive stories and insights from Benzinga reporters.
Biotech Stocks Surge: Coherus Up 9.09% in After-Hours Trading
- Coherus Performance: Coherus Oncology, Inc. (CHRS) rose 9.09% in after-hours trading, closing at $1.73 with a $0.14 gain, indicating strong investor confidence in its future prospects.
- Sensei Biotech Surge: Sensei Biotherapeutics, Inc. (SNSE) surged 10.06% after hours, finishing at $12.47 with a $1.14 increase, reflecting positive market expectations for its products.
- uniQure Significant Jump: uniQure N.V. (QURE) posted a 9.96% rise in after-hours trading, closing at $24.95 with a $2.26 gain, suggesting investor optimism regarding its R&D progress.
- IO Biotech Strategic Exploration: Although IO Biotech, Inc. (IOBT) had no fresh news on Thursday, its stock still gained 4.19%, closing at $0.50, indicating market interest in its exploration of strategic alternatives, including potential mergers or asset sales.
What Caused Sensei Biotherapeutics (SNSE) Stock to Surge Nearly 63% in After-Hours Trading?
Sensei Biotherapeutics Stock Surge: Sensei Biotherapeutics Inc. (SNSE) saw a significant increase of 62.88% in after-hours trading, reaching $17.20, following a closing price of $10.56, which was up 21.38% for the day.
Cambrian BioPharma Share Sales: Cambrian BioPharma Inc., a 10% shareholder, filed two Form 144 documents indicating plans to sell 27,066 common shares valued at $235,744, with transactions to be executed through Fidelity Brokerage Services LLC.
Stock Performance Overview: The stock of Sensei Biotherapeutics has increased by 2.52% year-to-date and 46.26% over the past six months, with a market capitalization of $13.32 million and trading between $5 and $18.35 over the last year.
BBAI Stock Momentum: BigBear.ai (BBAI) is trending with a momentum ranking in the 48th percentile, indicating strong long-term gains and stable performance in both short and medium terms.
Healthcare and Biotech Stocks Surge in After-Hours Trading: Sensei, Praxis, Cooper, Vanda, Cue, ResMed
Sensei Biotherapeutics Surge: Sensei Biotherapeutics Inc. saw a significant after-hours increase of 62.9% to $17.20, following a previous rise and a report of a narrower third-quarter net loss compared to the previous year.
Praxis Precision Medicines Progress: Praxis Precision Medicines, Inc. rose 24.8% to $237.10 after positive EMBOLD study results led to an early recommendation for stopping the study, with plans for an NDA filing in early 2026.
CooperCompanies Financial Update: The CooperCompanies, Inc. climbed 13.0% to $87.01 after reporting a fourth-quarter net income decline but positive revenue growth, alongside a strategic review to enhance shareholder value.
Vanda Pharmaceuticals FDA Approval: Vanda Pharmaceuticals Inc. gained 7.5% to $5.59 after the FDA lifted a partial clinical hold on a protocol, allowing for expanded dosing of tradipitant following a successful dispute resolution request.
Sensei Biotherapeutics Launches Strategic Review Aimed at Enhancing Shareholder Value
Company Decision: Sensei Biotherapeutics has decided to discontinue the development of solnerstotug and is conducting a strategic review to explore alternatives for maximizing shareholder value, which may include asset sales or mergers.
Workforce Reduction: The company plans to implement a workforce reduction to conserve cash while retaining a small team to manage compliance and the orderly cessation of ongoing clinical trials.
CEO Statement: CEO John Celebi acknowledged the clinical potential of solnerstotug but emphasized the need to prioritize funding and shareholder value in light of current market conditions.
Forward-Looking Statements: The company has issued caution regarding forward-looking statements, highlighting the uncertainties involved in the strategic review process and the potential risks associated with workforce reductions and operational wind-downs.
Post-Market Jump: Turn Therapeutics Soars 134% Following Nasdaq Debut; Biotech Stocks Rise
Surge in Biotech Stocks: U.S.-listed biotech and healthcare stocks experienced significant after-hours gains, with Turn Therapeutics Inc. leading the way, surging 134.29% after its Nasdaq debut.
Momentum and Anticipation: Other companies like Talphera Inc. and Ionis Pharmaceuticals Inc. also saw notable increases, driven by momentum and upcoming presentations, indicating a strong interest in the biotech sector.
HC Wainwright & Co. Maintains Buy on Sensei Biotherapeutics, Raises Price Target to $30
Fastest News Alerts: Benzinga Pro offers real-time intelligence and news alerts to help traders stay informed and make winning trades in the stock market.
Exclusive Community Access: Joining Benzinga Pro connects users with over 10,000 serious traders and provides access to exclusive stories and insights from Benzinga reporters.
